Skip to main content
Tesamorelin Research

Falutz 2010 — JCEM Pooled Phase 3 Analysis

Journal of Clinical Endocrinology and Metabolism

Falutz J, et al.

Summary

Pooled VAT treatment effect = -15.4% at 26 wk

Study Details
Study Design

Pooled analysis of two Phase 3 RCTs

Indication

HIV-associated lipohypertrophy

Intervention

2 mg SC daily

Species

Human

Sample Size

806 subjects

Risk of Bias Assessment

Industry-funded

Tags
SourcePooled AnalysisPhase3Tier 1
External Links
Metrics
Citations
0
Evidence QualityN/A
Related PeptideTesamorelin6 papers